#Rising demand for Non-oncology Biopharmaceuticals Market | Explore Tumblr posts and blogs

credenceresearchdotblog · 3 months ago

Text

The Oncology Biosimilars Market is projected to grow from USD 4725 million in 2024 to an estimated USD 23341.41 million by 2032, with a compound annual growth rate (CAGR) of 22.1% from 2024 to 2032. The oncology biosimilars market is rapidly emerging as a key segment in the biopharmaceutical industry. With increasing cases of cancer globally and the rising costs of innovative biologics, oncology biosimilars offer a cost-effective alternative while ensuring similar safety and efficacy profiles. This article delves into the market dynamics, trends, challenges, and future prospects of oncology biosimilars.

Browse the full report https://www.credenceresearch.com/report/oncology-biosimilars-market

Understanding Oncology Biosimilars

Biosimilars are biologic medical products that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, efficacy, or quality. In oncology, biosimilars address various cancers such as breast cancer, colorectal cancer, non-small cell lung cancer, and lymphoma. They replicate biologics like monoclonal antibodies and growth factors used in cancer treatment and supportive care.

Market Growth Drivers

1. Rising Cancer Incidence: According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with an estimated 20 million new cases in 2022 alone. This growing disease burden amplifies the demand for cost-effective treatment options, making oncology biosimilars a critical component of cancer care.

2. Cost-Effectiveness: Biosimilars are priced approximately 15-30% lower than their reference biologics, offering significant savings for healthcare systems and patients. This affordability is particularly impactful in low- and middle-income countries where access to expensive biologics is limited.

3. Patent Expirations: Several blockbuster oncology biologics, including trastuzumab (Herceptin) and bevacizumab (Avastin), have lost patent protection in recent years. This has paved the way for the entry of biosimilars, driving market competition and adoption.

4. Regulatory Support: Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established clear guidelines for the approval of biosimilars, encouraging pharmaceutical companies to invest in their development.

Key Market Trends

1. Expanding Product Portfolio: The oncology biosimilars market is witnessing an expansion in product offerings. Biosimilars for blockbuster drugs such as rituximab, pegfilgrastim, and cetuximab are gaining traction, with multiple players entering the space.

2. Increasing Approvals and Launches: Over the past decade, the FDA and EMA have approved numerous oncology biosimilars, including biosimilars for trastuzumab (e.g., Ogivri, Herzuma) and bevacizumab (e.g., Zirabev, Mvasi). These approvals have bolstered the market and enhanced access to affordable cancer treatments.

3. Collaborations and Partnerships: Pharmaceutical companies are increasingly entering strategic collaborations to enhance biosimilar development and commercialization. Partnerships between biotech firms, contract research organizations, and healthcare providers are streamlining market entry and expanding distribution networks.

4. Rising Acceptance Among Physicians: Initial skepticism surrounding biosimilars is gradually fading as real-world evidence demonstrates their safety and efficacy. Educational initiatives and clinical data are fostering confidence among oncologists and patients.

Challenges in the Market

1. Regulatory and Development Complexity: Developing biosimilars involves sophisticated processes and significant investment. Ensuring similarity in structure, function, and clinical outcomes with the reference biologic is challenging and time-consuming.

2. Market Competition: While competition drives innovation, it also exerts pressure on pricing and profitability. Companies must adopt innovative pricing strategies and differentiation approaches to capture market share.

3. Physician and Patient Perception: Despite increasing acceptance, some healthcare providers and patients remain cautious about switching from biologics to biosimilars. Addressing these concerns through education and robust clinical evidence is crucial.

Future Outlook

The oncology biosimilars market is poised for exponential growth, driven by factors like rising cancer prevalence, supportive regulatory frameworks, and ongoing technological advancements. By 2030, the market is expected to reach significant valuations, with Asia-Pacific and emerging markets playing a pivotal role due to their large patient populations and cost-sensitive healthcare systems.

Moreover, advancements in biosimilar manufacturing, including the use of artificial intelligence and machine learning, promise to reduce development timelines and costs. Governments and healthcare organizations worldwide are also likely to continue promoting biosimilar adoption through favorable policies and reimbursement frameworks.

Key Player Analysis:

Allergan (Ireland)

Amneal Pharmaceuticals LLC. (U.S.)

Apotex Inc. (Canada)

Aurobindo Pharma (India)

BIOCAD (Russia)

Bristol-Myers Squibb Company (U.S.)

Cipla Inc. (U.S.)

Eli Lilly and Company (U.S.)

Endo International plc (Ireland)

Hoffmann-La Roche Ltd. (Switzerland)

GlaxoSmithKline plc (U.K.)

Glenmark Pharmaceuticals Limited (India)

Lupin (India)

Mylan N.V. (U.S.)

Novartis AG (Switzerland)

Pfizer Inc. (U.S.)

Sanofi (France)

Sun Pharmaceutical Industries Ltd. (India)

Takeda Pharmaceutical Company Limited (Japan)

Teva Pharmaceutical Industries Ltd.(Israel)

Zydus Cadila (India)

Segmentation:

By Drug

G-CSF

Monoclonal Antibody

Hematopoietic Agents

By Disease Indication

Breast Cancer

Non-Small Cell Lung Cancer

Colorectal Cancer

Neutropenia

Blood Cancer

Leukemia

Myeloid Leukemia

Chronic Lymphocytic Leukemia (CLL)

Non-Hodgkin Lymphoma

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regional

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/oncology-biosimilars-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

healthcareanna · 5 months ago

Text

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

#healthcare #medical #health #medical devices #Biosimilars Market Size

0 notes

market-insider · 1 year ago

Text

Biomarker Testing Services: Transforming Healthcare Delivery and Patient Outcomes

The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

Gain deeper insights on the market and receive your free copy with TOC now @: Biomarker Testing Services Market Report Report

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

0 notes

deshmukh · 4 years ago

Link

The Global Non-oncology Biopharmaceuticals Market report provides information about the Global industry, including valuable facts and figures. This research study explores the Global Market in detail such as industry chain structures, raw material suppliers, with manufacturing The Non-oncology Biopharmaceuticals Sales market examines the primary segments of the scale of the market. This intelligent study provides historical data from 2015 alongside a forecast from 2020 to 2027.

#Rising demand for Non-oncology Biopharmaceuticals Market

0 notes

researchvishal · 2 years ago

Text

Radiopharmaceuticals Market To Undertake Strapping Growth By The End 2032 | FMI

The global radiopharmaceuticals market stands at US$ 6.2 Bn as of now and is expected to reach US$ 9.5 Bn by the year 2032 at a CAGR of 4.3% between 2022 and 2032.

Radiopharmaceuticals imply medications containing radioisotopes that could be used as both – therapeutic agents and diagnosis medications. Radiopharmaceuticals manage critical as well as chronic diseases. These days, various diagnostics are aimed towards organs with nuclear medicine radiopharmaceuticals.

PET and SPECT techniques are used in abundance while deploying radiopharmaceuticals. Some of the distinct features of radiopharmaceuticals include non-invasiveness, cost-effectiveness, easy of diagnosis, and higher sensitivity. Clinical applications include cardiology, oncology, lymphoma, and tumor.

Growing awareness regarding positive results provided by radiopharmaceuticals in checking chronic illness is one of the catalysts to radiopharmaceuticals market.

On the other hand, the fact that radiopharmaceuticals have half-life could restrain the market. It’s a known fact that radiopharmaceuticals involve higher investment. Short expectancy or half-life is one of the crucial factors restricting demand for radiopharmaceuticals. Thus, it’s only the developed regions who are able to increasingly adopt radiopharmaceuticals as of now. The developing economies still need to incorporate the technology to the fullest. Future Market Insights has walked through these functionalities with future prospects in its latest market study entitled ‘Radiopharmaceuticals Market’.

Key Takeaways from Radiopharmaceuticals Market

North America dominates the radiopharmaceuticals market due to rising frequency of cardiovascular diseases and cancer and the scenario is expected to persist even in the forecast period. Adopting innovative radioisotope production methods for treating chronic disorders is another reason.

Europe, led by the UK, is also expected to hold a significant market share due to the UK being subject to maximum incidences of cancer. Cancer Research UK estimate says that the UK alone houses 367,167 cancer patients.

The Asia-Pacific is poised to grow blatantly in the forecast period with it witnessing new product launches, collaborations, distribution agreements, acquisitions in an aplomb.

“The fact that radiopharmaceuticals are broadly used as biomarkers in molecular imaging is expected to take the radiopharmaceuticals market by storm in the upcoming period”, says an analyst from Future Market Insights.

Competitive Landscape

GE Healthcare inked an agreement with NorthStar Medical Radioisotopes, LLC for producing and distributing iodine-123 (I-123) capsules all across the US.

Bracco Diagnostics Inc., in March 2021, entered into partnership with CardioNavix, LLC for enhancing patients’ access to cardiac PET imaging. The new program is termed as ‘Bracco Mobile Isotope Service’, which ought to facilitate better patient care sites for providing cardiac PET imaging.

Jubilant Radiopharma, in August 2020, signed a MoU (Memorandum of Understanding) with Navidea Biopharmaceuticals, which focuses on an ELDA (Exclusive License and Distribution Agreement) for the latter’s diagnostic imaging agent called ‘Tilmanocept (technetium Tc 99m tilmanocept injection) in LATAM, Mexico, Canada, and the US.

Bayer AG, in June 2021, announced that it would acquire Noria Therapeutics Inc. along with PSMA Therapeutics Inc. with the objective of widening the former’s oncology portfolio that is into existence.

Norgine B.V., in March 2020, completed the acquisition of Azanta A/S, a specialty biopharmaceutical company. This included Nimorazole, a hypoxic radiosensitizer to treat cancer, and Angusta to facilitate labor induction.

Curium, in the year 2019, completed acquisition of MAP Medical, which would actually help it in strengthening the footprint all over the Europe with access to Baltic and Nordic countries.

The US FDA, in December 2020, completed approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11). It holds the distinction of being the very first drug for PET imaging for diagnosing prostate cancer.

Top Radiopharmaceuticals companies : Siemens AG,Positron Corporation,Novartis (Advanced Accelerator Applications),Curium,GE Healthcare,Lantheus Holdings Inc.,Sotera Health LLC (Nordion Inc.),Bayer AG,Eckert & Ziegler,

Key Segments Covered in the Radiopharmaceuticals Industry Analysis

Radiopharmaceuticals Market by Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

Radiopharmaceuticals Market by Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

Radiopharmaceuticals Market by Source:

Cyclotrons

Nuclear Reactors

Radiopharmaceuticals Market by End User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

0 notes

pranalipawarshinde · 2 years ago

Text

Nanomedicine Market | Future Growth Aspect Analysis to 2028

Nanomedicine Market Outlook 2028

The global nanomedicine market was valued at US$ 198.9 Bn in 2020

It is estimated to expand at a CAGR of 12.6% from 2021 to 2028

The global nanomedicine market is expected to reach the value of US$ 512.5 Bn by the end of 2028

Rising Prevalence of Chronic Diseases to Boost Nanomedicine Market

Nanomedicine is widely used in the treatment of chronic diseases such as cardiovascular diseases, diabetes, cancer, dementia, and others, where it aids in the rapid metabolism of medications in the body. Hence, rise in prevalence of chronic diseases is expected to boost the growth of the global market. Although the fields of medicine and healthcare have undergone incredible developments in the past few decades, with the introduction of breakthrough products and therapies such as portable imaging devices, non-invasive surgical tools, and advanced medical sensors, there still remains a wide gap between patient needs and available treatments.

Read Report Overview: https://www.transparencymarketresearch.com/nanomedicine-market.html

Advances in nanomedicine attempt at filling this gap. The promise of nanomedicines of delivering drugs at the target site in the right proportion and at the necessary rate of delivery will cater well to the needs of complicated disease conditions, significantly driving the global nanomedicines market. The market will also be significantly driven by the significant rise in the prevalence of chronic diseases across the globe.

Oncology a Lucrative Application Segment for Nanomedicine Market

The global naomedicine market is expected to witness tremendous growth opportunities due to rising incidences of oncology and chronic disorders across the globe. Due to rise in prevalence of cancer across the globe, nanomedicines plays an important role in the oncology segment. The vast rise in the number of cancer cases across the globe will continue to keep oncology one of the most lucrative application segments for nanomedicine over the forecast period as well. The nanomedicine market is significantly driven by factors such as increasing awareness among people about nanotechnology, rapidly increasing incidences of chronic illnesses, cancers, technological advancement, and rising investment in nanotechnology by government in several developing countries.

Request a Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1753

Rise in Awareness of Benefits of Nanomedicines Drives Global Market

Due to rising demand for nanomedicines, manufacturers are gaining lucrative growth opportunities in the global market. Nanomedicine is an expanding area of the healthcare industry, and is witnessing increasing acceptance in medical and healthcare applications. The global nanomedicine market features a low concentration of technology and nanomaterial suppliers. To lessen the brunt of the inevitable demand-supply gap resulting, owing to the low number of suppliers, manufacturers in the market mostly depend on long-term contracts with pre-negotiated terms and conditions for uninterrupted supply of raw materials in domestic markets. The vast funds required to excel in the technology- and research-driven field of nanomedicine have kept new players at a bay. The nanomedicine market is witnessing rapid growth due to increase in research and development activities across the globe.

Booming North America Nanomedicine Market

North America is expected to account for a major market share in the global nanomedicine market. Some of the major factors responsible for the market growth are well-established healthcare infrastructure and increasing number of biopharmaceutical companies in the region. The increasing prevalence chronic diseases all over the world demand for technologically advanced nanomedicines. The availability and adoption of nanomedical products such as nanorobots, DNA probes, monoclonal antibody-based immunoassays, nanosensors, and nanoparticle-based imaging agents are driving the market growth in nanomedicines. In addition, favorable regulatory environment is a key factor propelling the nanomedicine market in North America. Asia Pacific and Latin America are other attractive markets, which are poised to rise due to the increasing healthcare spending and improving healthcare facilities. This is due to economic growth, rise in spending capacity, surge in prevalence of cancers, and improvements in healthcare infrastructure.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1753

Nanomedicine Market: Overview

According to Transparency Market Research’s latest report on the global nanomedicine market for the historical period 2017–2019 and forecast period from 2021 to 2028, increase in research funding, rise in government support, improved regulatory framework, technological advancements, and surge in prevalence of chronic diseases are projected to drive the global nanomedicine market during the forecast period

Rise in Prevalence of Chronic Diseases such as Cancer and Cardiovascular Diseases: Key Driver

Cancer is a leading cause of death across the world. According to the International Agency for Research on Cancer, the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.

Diet is one of the key risk factors that leads to increase in number of patients with obesity and high blood pressure. Hence, change in dietary habits results in rise in prevalence of cardiovascular diseases. According to the Centers for Disease Control and Prevention, heart diseases account for nearly 655,000 deaths in the U.S. each year.

Aging is consistently reported as a major risk factor for neurodegenerative diseases. Therefore, surge in geriatric population contributes to the increase in number of patients with various brain diseases. An article published in the Journal of the Alzheimer's Association indicated that the prevalence of Alzheimer’s dementia increases dramatically with age; 3% of people aged 65 to 74, 17% of people aged 75 to 84, and 32% of people aged 85 or older have Alzheimer’s dementia.

Request Report Methodology: https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=1753

Improvement in Nanomedicine Technology Boosts Market Growth

Nanomedicine is a niche segment, with research & development as an integral part of the market. There is a need to identify and exploit the current technologies for nanomedicine such as nanocarriers, nanoparticles, and nanosensors to their full potential. Technologies such as targeted drug delivery, nanoparticle based diagnostic agents, and conjugated drug nanoparticles have already experienced an array of applications in the medical field.

Development of new technologies such as nanorobots, molecular nanotechnology (MNT), and nanovaccinology will open up new areas of applications and drive the nanomedicine market. The implications of lab-on-chip technology will be quite beneficial for the healthcare diagnostics market due to increased accuracy with reduced sampling size. Use of biomaterials in bone grafts and replacement therapies has improved the success rate and reduced complications in this segment. Hence, enhancement in the nanomedicine technology is expected to augment the market.

Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1753

High Cost of Nanomedicine Manufacturing R&D to Hamper Market

The nanomedicine market is concerned about both research and manufacturing costs as well as market price for the end-user. For a developing organization, nanomedicine research & development requires a large amount of resources, which raises worries about receiving finances.

Research activities involving new technology development require significant investment, which is expected to be received with significant profits by the innovator. Nanomedicine is a niche segment and requires high investment. This deters companies to enter the market due to uncertainty of receiving expected profit.

Nanomedicine Market: Competition Landscape

Sigma-Tau Pharmaceuticals, Inc.

Celgene Corporation

Mallinckrodt plc

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Merck & Co., Inc.

Pfizer, Inc.

GE Healthcare

UCB SA

Nanosphere, Inc.

CombiMatrix Corp

Abbott Laboratories, among others

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: 1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Blog: https://tmrblog.com Email: [email protected]

0 notes

metiresearchinfo · 3 years ago

Text

U.S. Real-World Evidence (RWE) Solutions Market Worth $2.01 billion by 2028- Exclusive Report by Meticulous Research®

According to a new market research report titled “U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2028”, published by Meticulous Research®, the U.S. real-world evidence solutions market is expected to grow at a CAGR of 13.0% from 2021 to 2028 to reach $2.01 billion by 2028.

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on a medical product’s use and potential benefits or risks. RWE can be produced through various study designs or analyses, not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success.

Download Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5243

Growth of this market is driven by key factors such as the growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare.

Impact of COVID-19 on the U.S. RWE Solutions Market

The COVID-19 pandemic has put a tremendous burden on the U.S. healthcare sector. As the COVID-19 outbreak continued to take its toll, real-world evidence (RWE) became the most influential emerging technology to fight against the COVID-19 outbreak. Real-world evidence solutions provided valuable insights to better understand, monitor, and prepare for the challenges caused by the COVID-19 pandemic. Technological advancements have made it possible to aggregate the data from conventional reporting tools and technology networks, such as mobile apps.

Real-world data (RWD), captured directly from patients or through medical claims or electronic medical records (EMRs), has the potential to support COVID-19 research in a better manner compared to randomized clinical trials (RCT). RCTs are now underway to evaluate existing and new therapies. Thus, there are opportunities for non-randomized RWE to provide information in the interim and answer additional real-world questions that are not addressed in the studies. Thus, the pandemic is expected to further propel the growth of the U.S. RWE market.

RWE Solutions Market: Future Outlook

The U.S. RWE solutions market study presents historical market data in terms of values (2019 and 2020), estimated current data (2021), and forecasts it for 2028– by Component (Datasets and Consulting Services), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post Market Surveillance, Medical Device Development & Approvals, and Other Applications), and End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users).

Based on component, the consulting & analytics segment is expected to show the fastest growth rate during the forecast period. Real-world evidence consulting service providers use robust real-world datasets generated by conducting prospective/observational studies to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development and increasing investments by biopharmaceutical companies in R&D. In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials.

You Can Buy Report Here @ https://www.meticulousresearch.com/Checkout/58313190

The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

Key companies operating in the U.S. RWE solutions market are IQVIA HOLDINGS INC. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), Flatiron Health (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings, Inc. (U.S.), and Symphony Innovation, LLC (U.S.).

Contact: Mr. Khushal Bombe Meticulous Market Research Inc. 1267 Willis St, Ste 200 Redding, California, 96001, U.S. USA: +1-646-781-8004 Europe : +44-203-868-8738 APAC: +91 744-7780008 Email- [email protected] Visit Our Website: https://www.meticulousresearch.com/ Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

0 notes

daisyri-me · 3 years ago

Text

Pharmaceutical Contract Manufacturing & Contract Research Market Expected to be Valued at USD 238.3 billion by 2025

Global Pharmaceutical Contract Manufacturing & Contract Research Market is anticipated to reach USD 238.3 billion by 2025. Contract manufacturing offers supports to the complete outsourcing market, due to its widespread adoption and popularity by pharmaceutical establishments. The factors that propel the growth of the Pharmaceutical Contract Manufacturing & Contract Research industry include decrease in the cost of production of APIs, increasing focus on cost reduction, the rising price pressure.

Free Exclusive Sample of this Report @ https://www.millioninsights.com/industry-reports/pharmaceutical-contract-manufacturing-contract-research-market/request-sample

On the other hand, there are factors that may hamper the growth of the market including stringent rules and regulations, and steady improvement. Pharmaceutical Contract Manufacturing & Contract Research Market is anticipated to grow at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe.

Pharmaceutical Contract Manufacturing & Contract Research industry may be explored by type, application, and geography. The market may be explored by product type as Finished Dosage Formulations (FDF); which may further include (Parenteral/Injectables, Tablet, Oral Liquids, Capsule, Others), Active Pharmaceutical Ingredients (API), OTC Medicines and Nutritional Products, Advanced Drug Delivery Products, and Others. The “Active Pharmaceutical Ingredients (API)” segment led the Pharmaceutical Contract Manufacturing & Contract Research Market in 2016 and is anticipated to maintain its dominance by 2025 due to increasing demand for High Potency Active Pharmaceutical Ingredients (HPAPI).

The key applications that could be explored in the Pharmaceutical Contract Manufacturing & Contract Research industry include Biopharmaceutical, and Pharmaceutical. The market by end users could span Non-sterile, and Sterile. North America accounted for the major share of the Pharmaceutical Contract Manufacturing & Contract Research Market Size in 2016 and will continue to lead in the forecast period. However, Asia Pacific is anticipated to raise at a surplus rate. The factors that could be attributed to the growth include increase in number of corporations outsourcing the schemes in the emerging economies.

Some of the key players that fuel the growth of the Pharmaceutical Contract Manufacturing & Contract Research industry comprise Pharmaceutical Product Development LLC, Catalent, AbbVie, Patheon, Baxter Biopharma Solutions, Dalton Pharma Services, Grifols International, S.A., and Lonza AG., and Boehringer Ingelheim Biopharmaceuticals GmBh. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.

Read Complete Report With TOC @ https://www.millioninsights.com/industry-reports/pharmaceutical-contract-manufacturing-contract-research-market

Market Segment:

Pharmaceutical Contract Manufacturing/Contract Research Market, Service Types Outlook (Revenue, USD Billion, 2014 - 2025) • Manufacturing Services (CMO) • API/Bulk Drugs • Advanced Drug Delivery Formulations Packaging • Packaging • Finished Dose Formulations • Solid Formulations • Liquid Formulations • Semi-solid Formulations • Research Services (CRO) • Oncology • Vaccines • Inflammation & Immunology • Cardiology • Neuroscience • Others

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email:[email protected]

#pharmaceutical contract manufacturing & contract research market

0 notes

credenceresearchdotblog · 3 months ago

Text

The Bispecific Antibodies Market is projected to grow from USD 5,740 million in 2024 to an estimated USD 106,123.6 million by 2032, with a compound annual growth rate (CAGR) of 44% from 2024 to 2032.The biopharmaceutical industry has witnessed significant advancements over the years, and bispecific antibodies (BsAbs) represent one of the most promising innovations in therapeutic development. These engineered molecules, capable of simultaneously binding to two different antigens or epitopes, have unlocked new possibilities for the treatment of complex diseases, particularly cancer, autoimmune disorders, and infectious diseases. As the global healthcare landscape continues to evolve, the bispecific antibodies market is experiencing remarkable growth.

Browse the full report https://www.credenceresearch.com/report/bispecific-antibodies-market

Market Overview

The bispecific antibodies market has grown exponentially in recent years, driven by increasing investments in research and development, breakthroughs in biotechnology, and rising prevalence of chronic diseases. According to market research, the global bispecific antibodies market is projected to expand at a compound annual growth rate (CAGR) exceeding 10% during the forecast period of 2023–2030. The market’s rapid growth is fueled by the development of innovative therapeutics and increasing adoption of precision medicine.

Key Drivers of Market Growth

1. Rising Incidence of Chronic Diseases The growing burden of cancer, autoimmune diseases, and other chronic conditions has created an urgent need for more effective and targeted therapies. Bispecific antibodies, with their unique ability to engage multiple targets simultaneously, are emerging as a powerful tool to address these challenges.

2. Advancements in Biotechnology Technological innovations such as antibody engineering, protein design, and novel manufacturing techniques have significantly enhanced the development of BsAbs. Platforms like the knob-into-hole technology and dual-variable domain immunoglobulin (DVD-Ig) are enabling the creation of bispecific antibodies with improved efficacy, stability, and manufacturability.

3. Increasing FDA Approvals and Product Launches Regulatory bodies like the U.S. Food and Drug Administration (FDA) have approved several bispecific antibody therapies in recent years, including blinatumomab (Blincyto) for leukemia and amivantamab (Rybrevant) for non-small-cell lung cancer. Such approvals not only validate the clinical potential of BsAbs but also encourage further investments in this space.

4. Rising Demand for Personalized Medicine Bispecific antibodies are at the forefront of personalized medicine, offering tailored therapeutic options based on individual patient profiles. Their ability to target specific pathways makes them particularly attractive for precision oncology.

Applications of Bispecific Antibodies

The therapeutic applications of bispecific antibodies are vast and diverse, including:

- Cancer Treatment: Bispecific T-cell engagers (BiTEs) like blinatumomab have revolutionized cancer therapy by redirecting T cells to tumor cells for targeted destruction. - Autoimmune Diseases: Bispecific antibodies are being explored for modulating immune responses, offering hope for patients with rheumatoid arthritis, psoriasis, and other autoimmune conditions. - Infectious Diseases: Novel BsAbs are being developed to neutralize viral infections by targeting both the virus and the host immune response.

Challenges in the Bispecific Antibodies Market

Despite their potential, the development and commercialization of bispecific antibodies face several hurdles:

1. Manufacturing Complexity: Producing bispecific antibodies is technically challenging due to their intricate structure and dual-targeting capabilities. Ensuring consistent quality and scalability remains a significant obstacle. 2. High Development Costs: The R&D costs for bispecific antibodies are substantially higher compared to conventional monoclonal antibodies, posing financial risks for smaller biotech firms.

3. Regulatory Challenges: The novel nature of bispecific antibodies requires tailored regulatory frameworks, which can delay approval timelines.

4. Safety Concerns: Off-target effects and immune-related adverse reactions pose risks during clinical development, necessitating rigorous safety assessments.

Future Outlook

The future of the bispecific antibodies market is bright, with a growing pipeline of innovative products and expanding therapeutic indications. Key players such as Amgen, Genentech, and Regeneron are investing heavily in the development of next-generation BsAbs with enhanced efficacy and reduced toxicity. Collaborative efforts between academia, biopharma companies, and contract research organizations are accelerating the pace of innovation.

Moreover, the integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is expected to further optimize the design and development of bispecific antibodies. Emerging markets in Asia-Pacific, Latin America, and the Middle East are also providing new growth opportunities due to increasing healthcare expenditure and improving access to advanced therapies.

Key Player Analysis:

Amgen, Inc.

Bayer AG

Dow Pharmaceutical Solutions

ImmunGene, Inc.

Immunocore Limited

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Hoffmann-La Roche AG

Segmentation:

Based on Type:

IgG-based Bispecific Antibodies

Non-IgG Bispecific Antibodies

Dual-target Bispecific Antibodies

Other Types

Based on Technology:

CrossMab Technology

Genetically Engineered Bispecific Antibodies

Double-targeted Single-chain Variable Fragments (scFvs)

Immune Cell-engaging Bispecifics

Other Technologies

Based on End-User:

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Hospitals and Clinics

Research and Academic Institutions

Other End-Users

Based on Region: • North America

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/bispecific-antibodies-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

esglatestmarketnews · 4 years ago

Text

Pharmaceutical Contract Manufacturing & Contract Research Market Analysis, Segmentation And Forecast Report till 2025

April 23, 2021: Global Pharmaceutical Contract Manufacturing & Contract Research Market is anticipated to reach USD 238.3 billion by 2025. Contract manufacturing offers supports to the complete outsourcing market, due to its widespread adoption and popularity by pharmaceutical establishments. The factors that propel the growth of the Pharmaceutical Contract Manufacturing & Contract Research industry include decrease in the cost of production of APIs, increasing focus on cost reduction, the rising price pressure.

Request a Free Sample Copy of this Report @ https://www.millioninsights.com/industry-reports/pharmaceutical-contract-manufacturing-contract-research-market/request-sample

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/pharmaceutical-contract-manufacturing-contract-research-market

Market Segment:

Pharmaceutical Contract Manufacturing/Contract Research Market, Service Types Outlook (Revenue, USD Billion, 2014 - 2025)

• Manufacturing Services (CMO)

• API/Bulk Drugs

• Advanced Drug Delivery Formulations Packaging

• Packaging

• Finished Dose Formulations

• Solid Formulations

• Liquid Formulations

• Semi-solid Formulations

• Research Services (CRO)

• Oncology

• Vaccines

• Inflammation & Immunology

• Cardiology

• Neuroscience

• Others

Pharmaceutical Contract Manufacturing/Contract Research Market Regional Outlook (Revenue, USD Billion, 2014 - 2025)

• North America

• U.S.

• Canada

• Europe

• Germany

• UK

• Asia Pacific

• India

• China

• Latin America

• Brazil

• Mexico

• Colombia

• Argentina

• Chile

• Venezuela

• Middle East and Africa (MEA)

• South Africa

Get in touch

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email: [email protected]

0 notes

healthcaremarketforecasters · 4 years ago

Text

Biosimilars Market is Experiencing Significant Growth Due to the Rising US$ 61.47 billion by 2025

Mar 08, 2021: Synopsis:

The scope of the global Biosimilars Market was appreciated by US$ 4.36 billion in 2016. It is projected to touch US$ 61.47 billion by the completion of 2025. It is likely to increase at a CAGR of 34.2% during the period of forecast. Most important biological medicines are upcoming the patent precipice. This is the greatest noteworthy motivating feature for the market. For example, Roche’s Mab Thera/Rituxan (rituximab), a monoclonal antibody biologic was accepted by the U.S. Food &Drug Administration (FDA) during November 1997 and its patent taken in the U.S.A, terminated in September 2016. A number of companies for example Pfizer, Amgen and Boehringer Ingelheim are concentrating on the development of biosimilars medication of rituximab.

Biosimilars are extremely matching to accepted biologic medicines. They have alike medicinal possessions by means of the effectiveness, safety, and the potency to original biologic goods. Greater occurrence of long-lasting illnesses for example anemia, cancer, lack of development hormone and diabetes, is likely to additionally power the growth of the market during the upcoming period.

Download sample Copy of This Report at: https://www.millioninsights.com/industry-reports/biosimilars-market/request-sample

Drivers:

The price efficiency of biosimilars medicines and greater occurrence of long-lasting complaints all over the world, are round about the most important reasons funding to the development of the market.

Entire prices of healthcare have augmented owing to the greater costs of patented medicinal preparations, particularly biologics. The administrations of numerous nation state are stressing on creation of price operative medication. The U.S.A. is well-known as the nation having the maximum health expenses. It has newly put stress on decreasing the expenses on healthcare. In the same way, price guideline in Japan and abridged budget of healthcare in India, have elevated the demands for price repression. This fetches the necessity for developing reasonably priced, better-quality, effective and new-fangled treatments. Hence, hard work to bring down healthcare payments is expected to increase the biosimilar market.

Read Complete Report With TOC @ https://www.millioninsights.com/industry-reports/biosimilars-market

Restraints:

Strict rules by the government for the development and manufacture of biosimilars could hamper the development of the biosimilars industry. Precise strategies are delivered by numerous governing establishments to uphold care profile and efficiency of planned medications. Dissimilar controlling organizations comprising China Food & Drug Administration, European Medicines Agency, U.S. Food & Drug Administration (FDA), have varied guidelines for endorsements of the medication. Existence of diverse guidelines make endorsement procedure of biosimilar medicine extremely time consuming and tiresome.

Classification:

The global biosimilars market can be classified by Application, Product, and Region. By Application, it can be classified as Growth Hormonal Deficit, Oncology, Chronic and Autoimmune Complaints, Blood Disorders, and others. By Product, it can be classified as Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins.

Regional Lookout:

By Region the global biosimilar industry can be classified as North America, Europe, Asia Pacific, and Rest of the World (RoW). Due to the existence of definite controlling background for biosimilars and the most important biopharmaceutical companies for example GlaxoSmithKline, Merck, AstraZeneca, Johnson & Johnson, Sanofi, Pfizer, and Novartis, Europe has retained the biggest share of the market by means of an income. Additionally, finely honed structure of healthcare and increasing number of product presentations have powered the development of the local market.

Get in touch

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email: [email protected]

Global Headquarters

Million Insights

Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States

Phone: 1-408-610-2300

Email: [email protected]

Asia Pacific

Million Insights

Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India

Phone: 91-20-65300184

0 notes

digitalconvo · 4 years ago

Text

RNA-Based Therapeutics And Vaccines Market Size, Implementation, Analytical Overview, Forecast To 2029

Global RNA-based Therapeutics and Vaccines Market: Overview

RNA-based biopharmaceuticals is a comparatively new class of treatment and it comprises vaccines and therapeutics. These biopharmaceuticals are prophylactic medicines that are used in the treatment of various rare and chronic diseases, which includes certain cardiovascular conditions, tuberculosis, diabetes, and cancer. The main objective of RNA therapeutics is to invent a cure for rare diseases and various unmet clinical conditions. This field is research-based and advancement made in the field of technology is likely to expand the global RNA-based therapeutics and vaccines market over the tenure of assessment.

Development of various promising technologies such as RNAi interference technology, SMaRT technology, and antisense technology are likely to offer promising growth opportunities for the global RNA-based therapeutics and vaccines market in the years to come.

The global RNA-based therapeutics and vaccines market has been classified based on product type, indication type, and region. The main objective of providing such a comprehensive report is to provide a deep insight into the market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6699

Global RNA-based Therapeutics and Vaccines Market: Notable Developments

The global RNA-based therapeutics and vaccines market has come across some path-breaking developments in the last few years. One of such developments shaping the course of the market is mentioned below:

In 2018, US-based Alnylam Pharmaceuticals, Inc and Regeneron Pharmaceuticals, Inc. have entered into a strategic collaboration to come up with RNAi therapeutics for the purpose of treatment of non-alcoholic steatohepatitis (NASH), a chronic liver disease.

Some of the key market players of the global RNA-based therapeutics and vaccines market are

Arrowhead Pharmaceuticals, Inc.

Moderna Therapeutics, Inc

Marina Biotech, Inc.

Alnylam Pharmaceuticals, Inc.

Arbutus Biopharma Corp.

Santaris Pharma A/S (A Roche Company)

Global RNA-based Therapeutics and Vaccines Market: Growth Drivers

Presence of Large of Patients with Infectious and Chronic Diseases to Generate Demand

The growth of the global RNA based therapeutics and vaccine market is likely to be influenced by the demand to find cure for infectious diseases and cancer. In addition, the pool of patient is very large, which is likely to emerge as another growth factor for the global RNA based therapeutics and vaccine market in the forthcoming years. The shortage of availability of alternative options of treatment for very rare diseases is likely to boost the demand for RNA-based therapeutics and vaccines over the period of analysis. Besides, augmented emphasis on the development of reimbursement policies by legislative bodies has triggered the development process of molecules of RNA.

Various non-profit organizations have made substantial financial investment for the advancement and development of RNA therapeutics. The rising demand for therapeutics in the treatment of various unmet medical conditions is likely to bolster growth of the global RNA based therapeutics and vaccine market in the years to come. On the other hand, high rates of failure and high cost involved with the research are expected to restrict development of the global RNA based therapeutics and vaccine market over the period of analysis.

To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6699

Global RNA-based Therapeutics and Vaccines Market: Regional Outlook

Of all the regions that have been analyzed in the report, North America is estimated to account for the most of the share in the global RNA based therapeutics and vaccine market. The growth of the region is ascribed to the high adoption rate of latest technologies. Besides, increased prevalence of various chronic diseases in North America is likely to augur well for the regional market in the times to come.

Asia Pacific is likely to emerge as another highly lucrative region in the global RNA based therapeutics and vaccine market. Substantial investment being made by government authorities for the development of the market in the years to come, which is likely to drive the demand in the region.

The global RNA-based Therapeutics and Vaccines market is segmented as:

Product Type

RNA-based Therapeutics

RNA-based Vaccines

Indication Type

Oncology

Immunology

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Genetic Diseases

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6699

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States

Tel: +1-415-520-1050

0 notes

sapanas · 4 years ago

Text

Soft Tissue Sarcoma Market: Latest Trends, Growth, And Profitability

The Industry report for “Global Soft Tissue Sarcoma Market” showcase by Market Research Future includes broad essential research alongside the detailed analysis of subjective and in addition quantitative angles by different industry specialists, key feeling pioneers to pick up a more profound understanding of the business execution.

Soft Tissue Sarcoma Market Insight

Treatment demand continues to grow for soft tissue sarcoma. Increased prevalence rate remains the major driver of the global soft tissue sarcoma market. Market Research Future (MRFR) reports that the global soft tissue sarcoma market is set to grow at 8.2% CAGR during the assessment period (2017-2023).

Soft tissue sarcoma is associated with various rare cancers, which includes clear cell sarcoma, angiosarcoma, alveolar soft-part sarcoma, malignant mesenchymoma, adult fibrosarcoma, clear cell sarcoma, rhabdomyosarcoma, and kaposi sarcoma. Presently, there are limited treatment options available for soft tissue sarcoma. However, the R&D pipelines are expected to grow in the forthcoming years. In addition, increased focus on pacing up approval process is likely to expand overall care and treatment quality for soft tissue sarcoma in the years to come. Sunitinib (sutent), doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and sirolimus (rapamune) are some of the pertinent drugs that are currently available. Nevertheless, adverse side-effects of the treatment, high cost and approval delays are some of the major market impediments.

Read more news on: https://www.medgadget.com/2019/05/soft-tissue-sarcoma-market-therapeutic-survey-report-2019-industry-growth-strategies-segmentation-application-technology-and-forecast-research-2023.html

Soft Tissue Sarcoma Market: Segmental Overview

The segmental analysis of the market has been conducted on the basis of disease type, treatment, end-users and distribution channel. Based on disease type, the market has been segmented into regional sarcoma, metastatic sarcoma, and local sarcoma. On the basis of treatment type, the market has been segmented into radiation therapy, anti-angiogenesis drugs, targeted therapy, and chemotherapy. The radiation therapy segment is further sub-segmented into external radiation therapy and internal radiation therapy. Based on end user, the market has been segmented into long-term care centers, oncology centers and hospital. Based on distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies and others.

Soft Tissue Sarcoma Market: Regional Segmentation

The regions covered in the report include the Middle East & Africa (MEA), Asia Pacific (APAC), Europe and the Americas. In terms of revenue, the global soft tissue sarcoma market is dominated by the Americas with North America being the brighter market. This is mainly owing to the presence of an advanced healthcare system in the region. Moreover, the rise in prevalence rate has also allowed the market to climb faster in the region. The data released by American Cancer Society, in 2016, approximately 12,390 people were suffering from soft tissue sarcoma or related cancer.

The market is also witnessing a steady growth in Europe. Higher rate of incidence and favourable reimbursement policies are some of factors that can be linked with the market growth in the region.

Asia Pacific (APAC) accounts for the third spot in the global soft tissue sarcoma market in terms of revenue. It is projected that the APAC soft tissue sarcoma market will witness a strong growth over the next couple of years. Healthcare policy reforms and increased efforts to improve healthcare services in countries such as China, India, Taiwan among others.

The Middle East & Africa (MEA) market is also expected to exhibit a healthy growth over the next couple of years. In MEA, much of the growth will be driven by the strong investment in healthcare sector in GCC countries.

Global Soft Tissue Sarcoma Market: Competitive Landscape

GlaxoSmithKline plc (U.K), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), and Teva Pharmaceutical Industries Ltd (Israel) are among key company discussed in the MRFR’s report.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304

Soft Tissue Sarcoma Industry News

Reportedly, the American pharmaceutical giant Eli Lilly has purchased the global rights for “CNTX-0290” the non-opioid pain candidate from Centrexion Therapeutics. The deal could garner close to $1 billion, plus royalties for the Boston-based company. CNTX-0290 is development phase and will be used for chronic pain associated with neuropathic, inflammatory and mixed pain conditions.

Epizyme, Inc, a late-stage biopharmaceutical firm focusing on new epigenetics therapies has recently released new data on on tazemetostat from the epithelioid sarcoma cohort of its active Phase 2 research in patients with molecularly defined solid tumours.

#Soft Tissue Sarcoma Market #Soft Tissue Sarcoma Market Size #Soft Tissue Sarcoma Market Share #Soft Tissue Sarcoma Market Growth #Soft Tissue Sarcoma Market Analysis #Soft Tissue Sarcoma Market Trends

0 notes

industryjournals · 5 years ago

Text

Computational Biology Market Size, Revenue Analysis, Top Vendors And Forecast Over The Period Till 2026

Wide application of computational biology in genomics, epigenomics, proteomics, and meta-genomics to understand 3D protein structural analysis, protein-protein interactions, and gene sequencing and expression along with increasing R&D in drug designing and disease modeling are key factors contributing to high CAGR of Computational Biology during the forecast period.

Market Size – USD 28.68 billion in 2018, Market Growth - CAGR of 21.7%, Market Trends –technological advancements, research and development of advanced computational tools

Get Free Sample: https://www.reportsanddata.com/sample-enquiry-form/2247

According to the current analysis of Reports and Data, the global Computational Biology market was valued at USD 2.86 billion in 2018 and is expected to reach USD 13.77 billion by the year 2026, at a CAGR of 21.7%. Science is massively benefitted from data proacessing, such as computational biology. Computational biology is an interdisciplinary field of biology that applies computational methods for analyzing biological data, such as genetic sequences, cell populations, and protein samples, to discover new predictions. The computational techniques used in computational biology include analytical methods, mathematical modeling, and simulation. Moreover, new technologies such as sequencing, and high-throughput experimental methods like microarray, yeast two-hybrid, and chip-chip assays are creating enormous and increasing amounts of data that can be analyzed and processed effectively and hassle-free using computational techniques.

The drive-in technological advancements have now opened the door to a world of innovation in the field of healthcare. Computational genetics is disciplinary of computational biology where homology and internal biological mechanism are studied using genome sequencing. The Human Genome Project is a classic example where the whole human genome was sequenced successfully. Computational biology also finds application in neurology, in which it is used to map complex interlinked pathways to visualize 3D simulation models of the brain. The medical advantage of computational biology is anticipated to boost the market during the forecast period. Additionally, computational pharmacology also uses tools of computational biology to visualize and simulate advanced drug-drug interactions in the drug designing process.

Government funding, increasing research and developments, increase in demand for predictive modeling and application in various sequencing projects, such as the human genome project, are some of the factors that support the market growth during forecast years. The rising demand for predictive models is, therefore, expected to boost the growth of the global computational biology market significantly. Moreover, the increasing funding from governments as well as private organizations for R&D in this field supports market growth. The widening application of computational tools in genomics, drug development programs & drug designing, and other such areas is expected to reduce the lead time of drug commercialization, therefore, reduce the average cost. However, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization and shortage of skilled workforce is likely to be a significant hindrance to market growth.

To Check Discount, Click Here: https://www.reportsanddata.com/discount-enquiry-form/2247

Further key findings from the report suggest

Computational Biology market is growing at a CAGR of 2% in Asia-Pacific due to owing to increased spending on research works in pharmacogenomics and pharmacokinetics in clinical studies for new drugs in the region.

In-house services are expected to be the fastest growing service segment during the forecast period 2019-2026. Several funding and R&D initiatives are undertaken by private institutions, and biopharmaceutical companies for the detection of a biomarker for drug development and disorder are driving the market growth.

North America region accounted for nearly 45% of the market share in 2018 owing to increasing R&D activities for drug discovery processes and development of new biological computation tools.

Several funding and R&D initiatives are undertaken by private institutions, and biopharmaceutical companies for the detection of a biomarker for drug development and disorder are driving the market growth.

Computational Genomics segment is expected to witness lucrative growth attributing to the recent technological advancements in cloud computing and other IT technologies. For instance, the Epidemiology and Genomics Research Program (EGRP) grants endowment to research-related activities and related need for personalization in healthcare owing to genetic variations, expanding application in non-oncology diseases,

Market players are adapting various organic and inorganic expansion strategies. For instance, Paragon Genomics Introduces CleanPlex CFTR Panel and unveils new fusion detection enables identification of known and novel gene fusions as diagnostic and prognostic markers for tumor progression. The CFTR Panel leverages Paragon Genomics' CleanPlex technology in a multiplex PCR-based targeted resequencing assay designed to simplify the evaluation of somatic and germline variants across the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Bioinformatics expanded to the development and the use of computational tools for the biological interpretation of the large amounts of data. There is a very heterogeneous scientific community that covers all aspects of today’s genetic research. In the coming years the commitment to bioinformatics and system biology will be extended even further with increased funding and explicit commitment to both of these areas.

Recently, in November 2019, Alibaba funded Hong Kong biotech firms to boost investments. The fund has invested in Hong Kong-based Prenetics, which provides genetics testing solutions for cancer screening and pharmacogenomics

The global Computational Biology market consists of major players like include Chemical Computing Group, Compugen, Simulation Plus, Genedata, Certara, Insilico Biotechnology, Accelrys, Rhenovia Pharma, Entelos, Nimbus Discovery, and Rhenovia Pharma

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/computational-biology-market

For the purpose of this report, Reports and Data has segmented the Computational Biology market on the basis of application, service, end use, and region:

Service Type (Revenue, USD Million; 2016–2026)

In-house

Contract

Application Type (Revenue, USD Million; 2016–2026)

Cellular & Biology Simulation

Computational Genomics

Database

Infrastructure / Hardware

Software & Services

Computational Proteomics

Pharmacogenomics

Others

Drug discovery and disease modeling

Target identification

Target Validation

Lead Discovery

Lead Optimization

Pre-clinical drug development

Pharmacokinetics

Pharmacodynamics

Clinical trials

Phase I

Phase II

Phase III

Human Body Simulation Software

End Use (Revenue, USD Million; 2016–2026)

Academics

Industry

Commercial

Regional Outlook (Revenue in USD Million; 2016–2026)

North America

U.S.

Canada

Europe

Germany

France

Spain

Italy

Rest of the Europe

Asia Pacific

China

India

Japan

Rest of Asia-Pacific

Middle East & Africa

Latin America

Brazil

0 notes

researchreportinsight · 6 years ago

Text

Clinical Trial Supplies Market Analysis by Application and Competitive Insights to 2025

11 April 2019 -Global Clinical Trial Supplies Market is anticipated to expand at a significant CAGR of 6.94% in the upcoming period as the scope, product types, and its applications are increasing across the globe. Clinical trial supply is responsible for offering clinical supplies needed for clinical studies of medical devices or drugs in accordance with the protocol and applicable regulatory necessities. The factors that propel the growth of the market include growth of biopharmaceutical industry, increase in a number of clinical trials, growing complexities, rising number of biosimilar and biologics drugs in trials, and development in supply chain management technology. On the other hand, a factor may hamper the growth of the market including the high cost of clinical trials. The market could be explored by clinical phase, product/service type, therapeutic use, end use, and geography.

Clinical trial supplies could be explored by clinical phase as Phase III, Phase II, Phase I, and Others. The “Phase I clinical trials” segment led the clinical trial supplies market in 2017 and will continue to lead in the forecast period. The key factors that may be attributed to the growth of market includes increasing number of Phase I clinical trials being outsourced, high investment in this sector, increasing globalization and less sample population for outsourcing the main volume of these trials.

View Full Report with TOC @ https://www.millioninsights.com/industry-reports/clinical-trial-supplies-market

Based on product/service type, the market could span Storage & distribution (Non-cold chain based, and Cold chain based), Manufacturing and Supply chain management. The market could be explored based on therapeutic use as Cardiovascular, CNS, Oncology, Metabolic disorders, Infectious disease, and Others. The “Oncology” segment led the market in 2017 and will continue to lead in the forecast period.

The market could be explored based on end use as a Medical device, Pharmaceuticals, and Biotechnology, Biologics and Others. The “Pharmaceuticals and Biotechnology” segment led the clinical trial supplies market in 2017 and will continue to lead in the forecast period. The key factors that may be attributed to the growth of the market includes increasing demand and increasing R&D activities in the biotechnological sector.

North America and Europe accounted for the major share of the clinical trial supplies market in 2017 and will continue to lead in the forecast period. The factors that could be attributed to the growth include a high share of clinical trials directed in this region and a better number of clinical trial supply companies with the most progressive technology. North America is followed by Asia-Pacific region owing to easy access to the patient, its diverse population, proximity to North America and low translation cost.

Some of the key players that fuel the growth of the clinical trial supplies market comprise Amerigroup, Alamo Group Ltd., Durbin plc, ADAllen Pharma, Biocair, KLIFO A/S, Movianto, Rubicon Research Pvt. Ltd., Catalent Pharma Solutions, Inc., Patheon, Inc., PCI Services, PAREXEL International Corporation, and Sharp Packaging Services. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.

Market Segment:

This report studies the global Clinical Trial Supplies market, analyzes and researches the Clinical Trial Supplies development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

• Alamc Group

• Catalent Pharma Solutions

• KLIFO A/S

• Movianto

• PCI Services

• Patheon

• PAREXEL International

• Sharp Packaging Services

• Biocair

• Thermo Fisher Scientific

Market segment by Regions/Countries, this report covers

• United States

• EU

• Japan

• China

• India

• Southeast Asia

Request Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/clinical-trial-supplies-market/request-sample

#Clinical Trial Supplies Market Report #Clinical Trial Supplies Market Demand #Clinical Trial Supplies Market Growth #Clinical Trial Supplies Market Forecast

0 notes

credenceresearchdotblog · 5 months ago

Text

The Immunomodulator Market is projected to grow from USD 88579.7 million in 2024 to an estimated USD 148816 million by 2032, with a compound annual growth rate (CAGR) of 6.7% from 2024 to 2032.The immunomodulator market has emerged as a critical component of global healthcare, driven by advancements in biotechnology, increasing incidence of autoimmune diseases, and the rising prevalence of cancer and infectious diseases. Immunomodulators, which regulate or modify the immune system, include immunosuppressants, immunostimulants, and others that either enhance or suppress immune activity. The growing awareness of immune-related disorders, coupled with the rise in biologics and personalized medicine, positions the immunomodulator market as one of the fastest-growing segments in the pharmaceutical industry.

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

Market Overview

The global immunomodulator market has witnessed remarkable growth in recent years, with significant advancements in therapies targeting autoimmune diseases, cancer, and chronic inflammatory conditions. According to market reports, the immunomodulator market is expected to grow at a compound annual growth rate (CAGR) of around 5-7% over the next decade. Several factors are driving this growth, including the increasing prevalence of diseases like rheumatoid arthritis, multiple sclerosis, lupus, and psoriasis, where the immune system malfunctions and attacks the body's tissues.

Moreover, immunomodulators have gained traction in oncology. They are used to boost the body's immune response against cancerous cells, which has made a significant impact on cancer treatment approaches. Additionally, the market is expanding in the area of infectious diseases, especially with the development of vaccines and treatments for diseases like COVID-19, HIV, and hepatitis.

Key Drivers of the Immunomodulator Market

1. Rising Prevalence of Autoimmune Diseases Autoimmune diseases have seen a sharp rise over the past few decades, with millions of people worldwide affected by conditions like type 1 diabetes, rheumatoid arthritis, Crohn’s disease, and systemic lupus erythematosus. The complex nature of these diseases often requires long-term treatment with immunomodulators to manage symptoms and prevent flare-ups, which has driven demand for more effective therapies.

2. Increase in Cancer Cases and Immunotherapy Adoption The integration of immunomodulators in cancer therapy, particularly in the form of checkpoint inhibitors and monoclonal antibodies, has revolutionized cancer treatment. Immunotherapy drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown great promise in treating cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma. The success of these therapies is driving further research and investment in this sector, increasing the market share of immunomodulators in oncology.

3. Advances in Biotechnology and Biopharmaceuticals The development of biopharmaceuticals has led to the creation of more targeted and effective immunomodulators. Unlike traditional drugs, biologics are derived from living organisms and are designed to mimic or enhance the body's natural immune response. The growing number of biopharmaceutical companies investing in research and development (R&D) of immunomodulators has fostered innovation, leading to novel therapies for hard-to-treat conditions.

4. Increasing Geriatric Population The aging population is another factor contributing to the growth of the immunomodulator market. As people age, their immune systems weaken, making them more susceptible to autoimmune diseases, cancers, and infections. Immunomodulators are increasingly being used to help manage these conditions in elderly populations, which is expected to contribute significantly to market growth.

Challenges and Limitations

Despite the promising growth, the immunomodulator market faces several challenges. One major issue is the high cost of biologic therapies, which can limit access to these treatments, especially in low- and middle-income countries. Additionally, side effects such as increased susceptibility to infections and certain types of cancer can be a concern for long-term users of immunosuppressants.

There is also the challenge of balancing immune suppression with immune enhancement. Suppressing the immune system too much can lead to infections, while overstimulating it may trigger autoimmune diseases. Therefore, finding the right therapeutic window for immunomodulators remains a challenge for healthcare providers and researchers.

Regional Insights

North America holds the largest share of the global immunomodulator market, primarily due to the high prevalence of autoimmune diseases and cancer, as well as the availability of advanced healthcare infrastructure and significant investment in R&D. Europe follows closely, with similar factors driving market growth, including favorable government policies that support biopharmaceutical innovation.

Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, attributed to the rising incidence of chronic diseases, increasing healthcare expenditure, and expanding biopharmaceutical industries in countries like China, Japan, and India. The growing middle class and improved access to healthcare services in these regions are further bolstering market expansion.

Future Outlook

The immunomodulator market is poised for sustained growth as researchers continue to unlock the complexities of the immune system. The ongoing development of new immunotherapies, combined with advancements in personalized medicine and targeted therapies, will likely drive innovation in this sector. Moreover, as healthcare systems around the world continue to prioritize the management of chronic diseases and cancer, the demand for immunomodulators will remain robust.

Key Player Analysis:

Abbott

Amgen Inc.

Biogen

Bristol-Myers Squibb Company

Eli Lilly and Company

Hoffmann-La Roche Ltd

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc

Segmentation:

By Product

Biologics,

Small molecules,

Other emerging therapies.

By Application

Autoimmune diseases,

Cancer,

Infectious diseases,

Others

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes